{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T23:09:45Z","timestamp":1785798585381,"version":"3.56.0"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T00:00:00Z","timestamp":1658534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Hartford Hospital"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>To date, no real-world data are available to describe cefiderocol use in carbapenem-resistant Acinetobacter baumannii (CRAB) meningitis. Furthermore, cefiderocol pharmacokinetic (PK) data to support CNS penetration in human subjects are limited. These gaps pose a significant concern for clinicians who are faced with treating such infections when considering cefiderocol use.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To describe cefiderocol CSF and plasma PK and pharmacodynamic (PD) data from two different dosing regimens [2\u2005g IV q6h (regimen 1) and 2\u2005g IV q8h (regimen 2)] during treatment of CRAB meningitis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and methods<\/jats:title>\n                  <jats:p>A 61-year-old woman with CRAB meningitis was treated with cefiderocol and intraventricular gentamicin. Steady-state plasma and CSF cefiderocol concentrations were evaluated on Day 19 (regimen 1) and Day 24 (regimen 2) during the cefiderocol treatment course.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>CSF AUC was 146.49 and 118.28\u2005mg\u00b7h\/L, as determined by the linear-log trapezoidal method for regimens 1 and 2, respectively. Penetration into CSF estimated as the AUCCSF\/AUCfree plasma ratio was 68% and 60% for regimens 1 and 2, respectively. Estimated free plasma and CSF concentrations exceeded the MIC of the isolate for 100% of the dosing interval. Microbiological and clinical cure were achieved, and no cefiderocol-associated adverse effects were observed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Cefiderocol, when given as 2\u2005g q8h and 2\u2005g q6h, attained CSF concentrations that exceeded the organism-specific MIC and the CLSI susceptible breakpoint (\u22644\u2005mg\/L) for 100% of the dosing interval.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkac248","type":"journal-article","created":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T08:19:09Z","timestamp":1658564349000},"page":"2737-2741","source":"Crossref","is-referenced-by-count":38,"title":["Plasma and cerebrospinal fluid concentrations of cefiderocol during successful treatment of carbapenem-resistant <i>Acinetobacter baumannii<\/i> meningitis"],"prefix":"10.1093","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7703-096X","authenticated-orcid":false,"given":"Wesley D","family":"Kufel","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, Binghamton University School of Pharmacy and Pharmaceutical Sciences , Binghamton, NY , USA"},{"name":"Division of Infectious Diseases, Department of Medicine, State University of New York Upstate Medical University , Syracuse, NY , USA"},{"name":"Department of Pharmacy, State University of New York Upstate University Hospital , Syracuse, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmeen","family":"Abouelhassan","sequence":"additional","affiliation":[{"name":"Center for Anti-Infective Research and Development, Hartford Hospital , Hartford, CT , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M","family":"Steele","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, State University of New York Upstate Medical University , Syracuse, NY , USA"},{"name":"Department of Pharmacy, State University of New York Upstate University Hospital , Syracuse, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramiro L","family":"Gutierrez","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, State University of New York Upstate Medical University , Syracuse, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talha","family":"Perwez","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, State University of New York Upstate Medical University , Syracuse, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Bourdages","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, State University of New York Upstate Medical University , Syracuse, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P","family":"Nicolau","sequence":"additional","affiliation":[{"name":"Center for Anti-Infective Research and Development, Hartford Hospital , Hartford, CT , USA"},{"name":"Division of Infectious Diseases, Hartford Hospital , Hartford, CT , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,7,23]]},"reference":[{"key":"2022093019460076500_dkac248-B1","author":"CDC","year":"2019"},{"key":"2022093019460076500_dkac248-B2","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1128\/CMR.00007-10","article-title":"Penetration of drugs through the blood-cerebrospinal fluid\/blood-brain barrier for treatment of central nervous system infections","volume":"23","author":"Nau","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"2022093019460076500_dkac248-B3","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/jac\/dkab015","article-title":"Cefiderocol: a novel siderophore cephalosporin for multidrug-resistant Gram-negative bacterial infections","volume":"76","author":"Parsels","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2022093019460076500_dkac248-B4","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2022093019460076500_dkac248-B5","doi-asserted-by":"crossref","first-page":"dlab188","DOI":"10.1093\/jacamr\/dlab188","article-title":"Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant Pseudomonas aeruginosa (DTR-P) infections","volume":"3","author":"Meschiari","year":"2021","journal-title":"JAC Antimicrob Resist"},{"key":"2022093019460076500_dkac248-B6","doi-asserted-by":"crossref","article-title":"Nosocomial neurosurgical meningitis due to XDR Pseudomonas aeruginosa: clinical experience with cefiderocol","author":"Stevenson","DOI":"10.1093\/jacamr\/dlac004.043"},{"key":"2022093019460076500_dkac248-B7","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1093\/cid\/ciaa1478","article-title":"Infectious Diseases Society of America guidance on the treatment of AmpC \u03b2-lactamase-producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections","volume":"72","author":"Tamma","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2022093019460076500_dkac248-B8","doi-asserted-by":"crossref","first-page":"S645","DOI":"10.1093\/ofid\/ofab466.1300","article-title":"Evaluation of penetration of cefiderocol into cerebrospinal fluid using a rat meningitis model","volume":"8","author":"Takemura","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2022093019460076500_dkac248-B9","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing\u2014Thirty-First Edition: M100","author":"CLSI","year":"2021"},{"key":"2022093019460076500_dkac248-B10","author":"Fetroja (cefiderocol) for injection, for intravenous use (package insert)","year":"2019"},{"key":"2022093019460076500_dkac248-B11","doi-asserted-by":"crossref","first-page":"ofab252","DOI":"10.1093\/ofid\/ofab252","article-title":"Cefiderocol pharmacokinetics in a patient receiving continuous venovenous hemodiafiltration","volume":"8","author":"Kobic","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2022093019460076500_dkac248-B12","doi-asserted-by":"crossref","first-page":"e0264620","DOI":"10.1128\/AAC.02646-20","article-title":"In vitro antibacterial activity of cefiderocol against multidrug-resistant Acinetobacter baumannii","volume":"65","author":"Abdul-Mutakabbir","year":"2021","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/10\/2737\/46223384\/dkac248.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/10\/2737\/46223384\/dkac248.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T20:10:40Z","timestamp":1664568640000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/77\/10\/2737\/6648989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,23]]},"references-count":12,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,7,23]]},"published-print":{"date-parts":[[2022,9,30]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkac248","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,10,3]]},"published":{"date-parts":[[2022,7,23]]}}}